A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development
aging and disease · 2025
DOI: 10.14336/ad.2025.0508 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift aging and disease, 2025. Verfasst von Alex Zhavoronkov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine US Inc., Cambridge, MA 02138, USA. Hauptthemen laut MEDLINE: Longevity, Drug Development, Research Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Although aging is increasingly recognized as a key factor in chronic disease management, preclinical drug development rarely incorporates direct assessments of lifespan. To date, no biotechnology company has conducted a full mouse lifespan study for a therapeutic agent prior to human clinical trials, despite widespread chronic use of many approved drugs. This oversight stems from a lack of standardized protocols for the incorporation of mouse lifespan studies, high costs, limited commercial incentives, and regulatory risks associated with long-term data. Here, we present a comprehensive and scalable protocol for conducting mouse longevity studies in the early stages of drug development. Being aware of monetary constraints in the drug discovery process, we propose a basic design for a longevity study on ~250 (176 males and 72 females) genetically heterogeneous mice (UM-HET3) per group, with survival curves as primary endpoint, and propose enhanced study design options only if budget allows. Our framework provides a standardized foundation for integrating longevity assessments into routine drug development, offering the potential to uncover long-term risks or benefits that traditional toxicology studies may overlook. Broad implementation of such protocols could support the development of safer and more effective therapeutics for chronic diseases, while opening new avenues for discovery of substances that could slow down the rate of aging, known as geroprotectors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Insilico Medicine US Inc., Cambridge, MA 02138, USA.
- Insilico Medicine AI Limited, Masdar, Abu Dhabi, United Arab Emirates.
- Insilico Medicine Hong Kong Ltd., Hong Kong SAR, China.
- Insilico Medicine Shanghai Ltd., Shanghai 201203, China.
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing 102609, China.
- Duke University, Durham, NC 27708, USA.
Zitieren
APA
Zhavoronkov, A., Wang, Q., Liu, Y., Hou, W., Shen, Y., Wilczok, D., Fortney, K., Aliper, A., Zhang, M., Ren, F., & Miller, R. A. (2025). A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development. aging and disease. https://doi.org/10.14336/ad.2025.0508
Vancouver
Zhavoronkov A, Wang Q, Liu Y, Hou W, Shen Y, Wilczok D, et al. A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development. aging and disease. 2025. doi:10.14336/ad.2025.0508
BibTeX
@article{Zhavoronkov2025,
author = {Zhavoronkov, Alex and Wang, Qian and Liu, Yujie and Hou, Wenbin and Shen, Yuelei and Wilczok, Dominika and Fortney, Kristen and Aliper, Alex and Zhang, Man and Ren, Feng and Miller, Richard A},
title = {A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development},
journal = {aging and disease},
year = {2025},
doi = {10.14336/ad.2025.0508}
}
EUVIMED